Markus Otto

33.6k total citations · 4 hit papers
391 papers, 16.3k citations indexed

About

Markus Otto is a scholar working on Neurology, Molecular Biology and Physiology. According to data from OpenAlex, Markus Otto has authored 391 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Neurology, 153 papers in Molecular Biology and 141 papers in Physiology. Recurrent topics in Markus Otto's work include Alzheimer's disease research and treatments (137 papers), Amyotrophic Lateral Sclerosis Research (73 papers) and Parkinson's Disease Mechanisms and Treatments (69 papers). Markus Otto is often cited by papers focused on Alzheimer's disease research and treatments (137 papers), Amyotrophic Lateral Sclerosis Research (73 papers) and Parkinson's Disease Mechanisms and Treatments (69 papers). Markus Otto collaborates with scholars based in Germany, United States and Italy. Markus Otto's co-authors include Jens Wiltfang, Petra Steinacker, Hayrettin Tumani, Albert C. Ludolph, Patrick Oeckl, Piotr Lewczuk, Johannes Kornhuber, S. Poser, Henrik Zetterberg and Christine A. F. Von Arnim and has published in prestigious journals such as Nature, The Lancet and Physical Review Letters.

In The Last Decade

Markus Otto

371 papers receiving 16.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neurofilaments as biomarkers in neurological disorders

2018 1.3k citations Markus Otto, Axel Petzold et al. profile →
Blood GFAP as an emerging biomarker in brain and spinal cord disorders

2022 427 citations Ahmed Abdelhak, Matteo Foschi et al. profile →
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

2019 345 citations Markus Otto et al. profile →
Virtually in this together – how web-conferencing systems enabled a new virtual togetherness during the COVID-19 crisis

2020 183 citations Janine Hacker, Jan vom Brocke et al. European Journal of Information Systems profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Markus Otto	6.2k	5.9k	5.3k	3.4k	2.9k	391	16.3k
Margaret A. Pericak‐Vance	7.0k 1.1×	4.8k 0.8×	2.9k 0.5×	1.5k 0.5×	2.0k 0.7×	340	18.4k
Seth Love	4.7k 0.8×	6.9k 1.2×	4.2k 0.8×	1.9k 0.6×	4.0k 1.4×	319	16.8k
Charlotte E. Teunissen	5.2k 0.8×	9.4k 1.6×	4.3k 0.8×	7.7k 2.3×	3.8k 1.3×	604	21.5k
Jonathan L. Haines	8.4k 1.4×	5.2k 0.9×	3.1k 0.6×	1.5k 0.5×	1.5k 0.5×	412	21.3k
Marcel M. Verbeek	4.1k 0.7×	5.1k 0.9×	4.4k 0.8×	2.2k 0.7×	2.2k 0.7×	294	12.9k
Elio Scarpini	3.8k 0.6×	4.1k 0.7×	2.2k 0.4×	1.7k 0.5×	3.2k 1.1×	369	12.9k
Ulf Andréasson	3.9k 0.6×	7.7k 1.3×	3.4k 0.6×	4.9k 1.5×	2.5k 0.8×	178	13.7k
Peter Paul De Deyn	5.5k 0.9×	6.5k 1.1×	3.3k 0.6×	4.9k 1.5×	4.1k 1.4×	623	24.7k
Catriona McLean	7.1k 1.1×	6.4k 1.1×	2.9k 0.5×	1.1k 0.3×	2.5k 0.9×	471	19.5k
Thomas J. Montine	8.7k 1.4×	10.8k 1.8×	6.7k 1.3×	4.2k 1.3×	5.2k 1.8×	439	27.1k

Countries citing papers authored by Markus Otto

Since Specialization

Citations

This map shows the geographic impact of Markus Otto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Otto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Otto more than expected).

Fields of papers citing papers by Markus Otto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Otto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Otto. The network helps show where Markus Otto may publish in the future.

Co-authorship network of co-authors of Markus Otto

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Otto. A scholar is included among the top collaborators of Markus Otto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Otto. Markus Otto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mayer, Tobias, Ilka Schneider, Gisela Stoltenburg‐Didinger, et al.. (2025). Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle. Neuropathology and Applied Neurobiology. 51(3). e70019–e70019.

Halbgebauer, Steffen, Gabriele Nagel, Angela Rosenbohm, et al.. (2025). Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood. Clinical Chemistry. 71(12). 1234–1242.

Bachhuber, Franziska, Johannes Dorst, Željko Uzelac, et al.. (2025). Comparative analysis of cerebrospinal fluid neurofilament medium, light and heavy chain in neurodegenerative diseases using an in-house assay for the detection of neurofilament medium chain. EBioMedicine. 120. 105930–105930.

Barba, Lorenzo, Giovanni Bellomo, Daniel Alcolea, et al.. (2025). Serum level changes of the synaptic marker beta-synuclein in Alzheimer’s disease continuum and other dementias. Journal of Neurology Neurosurgery & Psychiatry. 96(12). jnnp–2025.

Barba, Lorenzo, Lucio D’Anna, Samir Abu‐Rumeileh, et al.. (2025). Implementing Blood Biomarkers in Stroke Research and Clinical Practice. Stroke. 56(8). 2380–2384. 1 indexed citations

Seifert, Michael, et al.. (2024). Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis. Brain Communications. 6(5). fcae288–fcae288. 5 indexed citations

D’Anna, Lucio, Samir Abu‐Rumeileh, Giovanni Merlino, et al.. (2024). Safety and Outcomes of Mechanical Thrombectomy in Acute Ischemic Stroke Attributable to Cardiological Diseases: A Scoping Review. Journal of the American Heart Association. 13(17). e034783–e034783. 5 indexed citations

Massa, Federico, Samir Abu‐Rumeileh, Lorenzo Barba, et al.. (2023). Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease. Journal of Neurology. 271(4). 1999–2009. 4 indexed citations

Witzel, Simon, Jeffrey Statland, Petra Steinacker, et al.. (2023). Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis—insights from a completed randomized controlled trial with rasagiline. European Journal of Neurology. 31(3). e16154–e16154. 5 indexed citations

10.

Barba, Lorenzo, Samir Abu‐Rumeileh, Steffen Halbgebauer, et al.. (2023). CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology. 101(1). e50–e62. 24 indexed citations

11.

Hahn, Lisa, Simon B. Eickhoff, Karsten Mueller, et al.. (2023). Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems. eLife. 13. 4 indexed citations

12.

Rumund, Anouke van, et al.. (2022). Factors associated with mortality in early stages of parkinsonism. npj Parkinson s Disease. 8(1). 67–67. 6 indexed citations

13.

Massa, Federico, et al.. (2021). Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission. 129(2). 207–230. 60 indexed citations

14.

Stürner, Klarissa Hanja, Oliver Werz, Andreas Koeberle, et al.. (2020). Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. Scientific Reports. 10(1). 8776–8776. 5 indexed citations

15.

Aktaş, Orhan, André Huss, Klaudia Lepka, et al.. (2020). Serum neurofilament light chain. Neurology Neuroimmunology & Neuroinflammation. 7(6). 33 indexed citations

16.

Hacker, Janine, et al.. (2020). Virtually in this together – how web-conferencing systems enabled a new virtual togetherness during the COVID-19 crisis. European Journal of Information Systems. 29(5). 563–584. 183 indexed citations breakdown →

17.

Marques, Tainá M., Anouke van Rumund, Patrick Oeckl, et al.. (2019). Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 92(13). e1479–e1486. 95 indexed citations

18.

Ballarini, Tommaso, Franziska Albrecht, Karsten Mueller, et al.. (2019). Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. NeuroImage Clinical. 25. 102112–102112. 11 indexed citations

19.

Devos, David, Caroline Moreau, Maéva Kyheng, et al.. (2019). A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports. 9(1). 2918–2918. 114 indexed citations

20.

Denk, Johannes, Johannes Kornhuber, Jens Wiltfang, et al.. (2018). Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE. 13(5). e0197329–e0197329. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact